Home » Stocks » DCPH

Deciphera Pharmaceuticals, Inc. (DCPH)

Stock Price: $45.90 USD 0.70 (1.55%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 2.60B
Revenue (ttm) 42.09M
Net Income (ttm) -266.49M
Shares Out 55.78M
EPS (ttm) -4.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $45.90
Previous Close $45.20
Change ($) 0.70
Change (%) 1.55%
Day's Open 45.15
Day's Range 44.64 - 46.17
Day's Volume 576,248
52-Week Range 39.42 - 68.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

With the trading day about halfway over, the broad markets largely were pushing higher, except for the Dow Jones industrial average.

Other stocks mentioned: BB, LRCX, SHOP, ZM, BHP, SQ, ZYME
2 weeks ago - 24/7 Wall Street

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furt...

4 weeks ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barc...

1 month ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB ...

2 months ago - Business Wire

Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.

2 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 5.17% and 4.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...

2 months ago - Zacks Investment Research

Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 16.03% year over year to ($1....

2 months ago - Benzinga

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a business update. ...

2 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Gugg...

2 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021. ...

2 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, t...

3 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Heal...

3 months ago - Business Wire

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Other stocks mentioned: BMRN, QURE, RGNX
4 months ago - Zacks Investment Research

Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.

4 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and ...

4 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, t...

4 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, h...

4 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced data presentations from clinical studies of QINLOCK, the Company's switch-control tyrosine kinase inhibito...

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014, a highly...

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London He...

5 months ago - Business Wire

Deciphera (DCPH) reports a narrower-than-expected loss and sales beat estimates in the third quarter of 2020.

5 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

PETACH TIKVA, Israel and WALTHAM, Mass., Nov. 6, 2020 /PRNewswire/ -- Medison Pharma, a leading international commercial partner for highly innovative therapies, today announced an exclusive distributio...

5 months ago - PRNewsWire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results and provided a business update for the third quarter ended September 30, 2020. “The stron...

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In connection w...

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

7 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

7 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

8 months ago - Business Wire

Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 10.45% and 249.26%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the Australian Therapeutic Goods Administration (TGA) has approved QINLOCK™ (ripretinib), a switch-con...

9 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall su...

9 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sa...

9 months ago - Business Wire

Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.

Other stocks mentioned: BPMC
10 months ago - The Motley Fool

After 17 years of clinical work, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) finally has a marketable product.

10 months ago - Benzinga

Approval of its cancer-fighting drug could make all the difference.

10 months ago - The Motley Fool

The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.

11 months ago - Zacks Investment Research

Deciphera stock popped Monday after the biotech gained FDA approval for a stomach cancer treatment. The drug, known by brand name Qinlock, treats gastrointestinal stromal tumors.

11 months ago - Investors Business Daily

Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.25% and -97.52%, respectively, for the quarter ended March 2020.

11 months ago - Zacks Investment Research

Deciphera (DCPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

Blueprint Medicines Corp (NASDAQ: BPMC) shares were taking a beating Tuesday after the company announced a negative late-stage readout for its lead asset avapritinib in third- or fourth-line gastrointes...

11 months ago - Benzinga

Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

What should investors think of this late-stage cancer biotech?

11 months ago - The Motley Fool

Deciphera Pharmaceuticals: Updates To Thesis, Expecting A Rebound Ahead Of August PDUFA

1 year ago - Seeking Alpha

Investors are concerned that an important regulatory deadline for the development-stage drug developer will be delayed because of the coronavirus pandemic.

1 year ago - The Motley Fool

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment... [Read more...]

Industry
Biotechnology
IPO Date
Sep 28, 2017
CEO
Steven Hoerter
Employees
350
Stock Exchange
NASDAQ
Ticker Symbol
DCPH
Full Company Profile

Financial Performance

In 2020, DCPH's revenue was $42.09 million, an increase of 68.35% compared to the previous year's $25.00 million. Losses were -$266.49 million, 38.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is 75.73, which is an increase of 64.99% from the latest price.

Price Target
$75.73
(64.99% upside)
Analyst Consensus: Buy